Placental Stem Cell Therapy to Treat Acute Radiation Syndrome Receives Boost from FDA

In collaboration with Pluristem Therapeutics, the Hadassah Medical Organization developed a stem cell product from the human placenta to prevent and treat acute radiation syndrome (ARS). The product, PLX-R18, has just received orphan drug status from the U.S. Food and Drug Administration (FDA).                                                                                                                                            “Receiving orphan drug designation brings us…